After largely being an unknown risk previously, medical researchers examined MGUS and familial risk in a study. Here’s a look at what was learned from the study, other MGUS incidence information, and MGUS screening recommendations.

Will telemedicine remain as a mainstay for myeloma patients after the pandemic? Learn the prime points from the Myeloma TelemEDucation Empowerment Resource Center.

New research from Heinz Ludwig, MD et al explores the global interrelations between Multiple Myeloma (MM) mortality and countries’ economic resources, patient empowerment, and health access and quality. The study is intended to inform about the associations between these factors, and to improve diagnosis, management, and outcome of patients globally.

Studies centering on vaccinations for myeloma patients have been limited in the past due to their low participation rate in trials coupled with negligent measures of patient outcomes. Learn about compilation of vaccination data.

Myeloma experts Dr. Sikander Ailawadhi and Dr. Saad Usmani share disparities in age of diagnosis for MGUS and active myeloma in BIPOC patients.

The Patient Empowerment Network Diverse Partners in Your Myeloma Care program focuses on helping to improve health outcomes for underserved myeloma patients. We’ll take a look at what we know, what we’ve learned, and what help and resources are needed to continue advancing care for BIPOC myeloma patients.

Dr. Victoria Vardell discusses her study where key findings reveal Black patients are less likely to receive a stem cell transplant (SCT).

Myeloma expert Dr. Sikander Ailawadhi of Mayo Clinic breaks down the importance of treatment adherence and disease management in multiple myeloma.

Expert Dr. Sikander Ailawadhi discusses disparities around access to care in multiple myeloma,

Dr. Ajay Nooka shares why this is a good time in myeloma research and the important work that remains around treatment disparities for people of color.

Dr. Sikander Ailawadhi provides high-level highlights for multiple myeloma from the 61st American Society of Hematology (ASH) Meeting.